Business
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S Copenhagen, Denmark, 13 November 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), announces that the private placement of 40,438,426 new shares has been completed. The initiation of the private placement was announced in Announcement no. 24. Jens Due Olsen, Chair of the Board of BioPorto, commented: “We
About this update from Bioporto A/s
[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"13 November 2025","length":16,"tagName":"p"},{"type":"text","content":"Announcement no. 25","length":19,"tagName":"p"},{"type":"text","content":" ","length":432,"tagName":"p"},{"type":"text","content":"Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S","length":124,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, 13 November 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), announces that the private placement of 40,438,426 new shares has been completed. The initiation of the private placement was announced in Announcement no. 24.","length":274,"tagName":"p"},{"type":"text","content":"Jens Due Olsen, Chair of the Board of BioPorto, commented: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by a strong commitment from BioPorto’s Board and management. The private placement provides the financial flexibility to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the Validation Study in BioPorto’s U.S. clinical trial, while strengthening our commercial platform. In determining the size of this placement, the Board considered the Company’s range of future financing options, primarily in the form of potential divestments of non-core a...